Document is current
Any future updates will be listed below
-
Authors
Bharathy, Narendra
Berlow, Noah E.
Wang, Eric
Abraham, Jinu
Settelmeyer, Teagan P.
Hooper, Jody E.
Svalina, Matthew N.
Bajwa, Zia
Goros, Martin W.
Hernandez, Brian S.
Wolff, Johannes E.
Pal, Ranadip
Davies, Angela M.
Ashok, Arya
Bushby, Darnell
Mancini, Maria
Noakes, Christopher
Goodwin, Neal C.
Ordentlich, Peter
Keck, James
Hawkins, Douglas S.
Rudzinski, Erin R.
Mansoor, Atiya
Perkins, Theodore J.
Vakoc, Christopher R.
Michalek, Joel E.
Keller, Charles https://orcid.org/0000-0003-2505-7487
-
Funding
Funding for this research was provided by:
National Institute of Health (5R01CA189299, 1R01CA143082)
- License Information
-
More Information
Article History
Received: 10 January 2019
Accepted: 17 April 2019
First Online: 21 May 2019
Ethics approval and consent to participate
: All animal studies were conducted with the approval of IACUC.
: Not applicable.
: C.K. received an unrestricted grant from Syndax Pharmaceuticals that supported third-party testing of ENT in PDXs. P.O. is an employee of Syndax Pharmaceuticals. J.E.W. is an employee of AbbVie Pharmaceuticals. Unrelated to this study, C.K. has had sponsored research agreements with Eli Lilly and Roche-Genentech, and N.E.B. is a scientific officer at First Ascent Biomedical Corp. C.R.V. is an advisor to KSQ Therapeutics and receives research funding from Boehringer-Ingelheim. D.S.H. has received reimbursement for travel to Medical Advisory Board meetings for Loxo Oncology, Bristol-Myers Squibb, Celgene, and Bayer but no compensation otherwise. All other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
